Fig. 1

IGF2BP3 expression in normal and cancer tissues. A Comparison of IGF2BP3 mRNA levels between tumor and normal tissue across TCGA cancer types by analyzing integrated data from the TCGA and GTEx databases. B–D IGF2BP3 mRNA levels in bladder cancer samples from the TCGA BLCA dataset, categorized by T stages, N stages, and histologic grade. E–H IGF2BP3 mRNA levels in bladder cancer samples from the E-TABM-147 dataset, categorized by tissue type (normal vs. cancer), T stages, N stages, and histologic grade. I–M IGF2BP3 mRNA levels in bladder cancer samples from the “Sanchez-Carbayo bladder 2” dataset, categorized by tissue type, T stages, N stages, histologic grade, and muscle-invasive type. N–P IGF2BP3 mRNA levels in bladder cancer samples from the GSE48075 dataset, categorized by T stages, N stages, and M stages. Q–R IGF2BP3 mRNA levels in bladder cancer samples from the GSE120736 dataset, categorized by muscle invasive type and histologic grade. S Representative immunohistochemical images of IGF2BP3 in normal bladder tissue, low-grade and high-grade bladder cancer tissues in Human Protein Atlas (HPA). The percentage of different staining intensities in each type of tissue is shown in a stacked bar graph. **** p < 0.0001, *** p < 0.001, ** p < 0.01, * p < 0.05